Combined analysis of +100 acidic and basic drugs in human whole blood using the SCIEX QTRAP® 5500 LC-MS/MS System
Timothy Fassette1, Afton Martinez1, Colleen Moore1, and Pierre Negri2
1Henderson Forensic Laboratory, US; 2SCIEX, US
Recently, there has been a steady increase in the number of police officers submitting DUI analysis requests to screen for drugs they suspect the driver may be under the influence of. These requests have dramatically increased since the sale of recreational marijuana in state licensed stores became legal on July 1st, 2017 in Nevada. The DUI testing policy for the forensic toxicology laboratory at the time was that any DUI whole blood sample with a blood alcohol concentration (BAC) above 0.084% (taking uncertainty of measurement into account) would not go onto further testing to determine if there were also any drugs in the driver’s blood at the time of the incident. Following a retrospective study on adjudicated whole blood DUI casework in late 2017, the Henderson Police Department’s Forensic Toxicology Laboratory found that approximately 60% of the DUI cases from this study that were not previously analyzed due to having a BAC above 0.084% also had drugs in their system at the time of the incident in which they were arrested. These findings prompted the development of a rapid, robust and selective screening method for positive identification of a panel of specific drugs.Â
In this technical note, a sensitive and reliable workflow using the SCIEX QTRAP 5500 System for sub-nanogram per mL detection of drugs in human whole blood is presented. This targeted screening method is shown to provide a quantitative workflow enabling rapid and confident identification of multiple drugs in a whole blood sample for high-throughput screening.Â
Â
Sample preparation: A total of 98 target analytes were screened in this workflow. They consisted of 35 Rx depressants, 16 benzodiazepines, 17 stimulants, 13 opiates, 12 THC/synthetic cannabinoids, 3 synthetic cathinones and 2 OTC-depressants. The full list of analytes included in this panel is summarized in Table 1. Extraction of whole blood samples was performed using the UCT QuEChERS extraction kits according to procedures shown in Figure 2. Following the SPE procedure, 5 µL of the reconstituted solution were injected for each compound.
HPLC conditions: The separation was performed on a Shimadzu Prominence UFLC system using a Phenomenex Kinetex® phenyl-hexyl column (50x4.6mm, 2.6µm, 00B-4495-E0). Mobile phase A (MPA) and mobile phase B (MPB) were ammonium formate with formic acid in water and formic acid in methanol, respectively. The total HPLC runtime was 12 minutes.Â
Mass spectrometry: Analysis was performed on the SCIEX QTRAP® 5500 System with Turbo Vâ„¢ Source and Electrospray Ionization (ESI) probe. A targeted drug screening method was developed using a highly sensitive and selective Multiple Reaction Monitoring (MRM) survey scan, followed by full scan MS/MS analysis (EPI – Enhanced Product Ion scan) on the detected analytes using the linear ion trap mode. A schematic of the workflow used for this targeted screening experiment is shown in Figure 3.Â
Data processing: MS/MS library searching was used for confirmation of detected compounds in the linear ion trap using MultiQuant™ Software with Analyst® Software Reporter.
Also listed in Table 1 is the cutoff concentration set for each analyte in the screening method. This cutoff is based on therapeutic potency for each drug, and a positive result in the drug screen is any result that is above that cutoff concentration for a particular analyte. The cutoff concentration for each analyte in the screening method also corresponds with the LOQ for the quantitative method used for each analyte, such that any drug detected below the LOQ is excluded from quantitative analysis.
The QTRAP 5500 System is a hybrid triple quadrupole linear ion trap mass spectrometer which allows acquisition of a selective MRM survey scan followed by an EPI scan (full scan MS/MS) which is triggered when signal is detected for each specific MRM transition. The use of MRM selected screening and MS/MS library searching allows for great selectivity even among structurally related analytes eluting off the column at similar retention times. The acquired full scan MS/MS spectra contain the complete molecular fingerprint of the compounds and can be searched against relevant spectral libraries for confident identification using spectral library database searching. This approach provides accurate compound confirmation which significantly reduces the risk of false positives in the unknown samples. Using this comprehensive screening method, 98 different compounds were readily detected and identified in a 12-minute analysis. Figure 4 shows extracted ion chromatograms (XICs), MS/MS spectra with MS/MS matched library spectra for morphine (A) and amphetamine (B). The MS/MS spectra allowed the positive identification of these compounds through spectral library searching.Â
Data was acquired with Analyst 1.7 Software and processed with MultiQuant Software 3.0.3. A processing method for the 98-analyte panel was developed to analyze the time-scheduled MRM data. Detection and integration of the peaks from the background was easily accomplished using MultiQuant Software. The correct peak was automatically selected within the viewing window based on the MRM transition of each compound, reducing the chance of calling peaks from other closely eluting compounds.Â
Â
Following the creation of a robust processing method, calibration curves were generated to determine the limits of quantification (LOQ). The method showed great sensitivity as it was able to readily detect ions down to 0.5 ng/mL. The limit of detection for the concentration of each cutoff control sample in the method was easily discernable from negative samples that were run. The Scheduled MRM algorithm used in this workflow aided in the acquisition of many more compounds by collecting MRM transitions just around the expected elution time for each compound, resulting in an increase of data quality and confidence in forensic analyte detection at sub ng/mL concentration levels. The use of the QTRAP 5500 System provided speed and sensitivity to the assay while allowing streamlined identification of drugs present in the case samples at different concentrations in a single analytical workflow. Combining this high quality quantitation data with the library matching, this screening method enables improved robustness without the false positive and false negative results that are commonly seen with other screening methods used in forensic toxicology laboratories.
Â
The data analysis component of MultiQuant Software is designed to provide a centralized results grid for streamlined review and efficient case sample report processing. One of the advantageous features of the software is that a case sample report can easily be generated for each sample at the click of a button. The report is highly customizable and contains detailed information on sample, instrument and other relevant information such as experimental conditions and data processing parameters. In addition, retention time errors, peak area and purity scores can be automatically calculated and visualized in the Analyst Software Reporter.
Figure 5 shows a customized sample report generated following the analysis of a case sample using the Scheduled MRM algorithm previously described. Eleven drugs were accurately identified in the case sample based on the MRM transition peak areas, retention times and purity scores from matched MS/MS. The streamlined data processing made possible by Analyst Software Reporter provided a simplified interface for fast data analysis and quick sample report generation to maximize the forensic laboratory operational efficiency. A comprehensive sample report containing all the relevant case sample report information can be easily created at the click of a button, increasing throughput and efficiency in the toxicology laboratory. The results generated provide both qualitative data and quantitative confirmation in a single and comprehensive report.
Â
The combination of a solid phase extraction (SPE) procedure and optimized chromatography with the highly sensitive QTRAP 5500 System allowed quick and reliable identification of 98 target compounds for DUID testing. This workflow enabled sub-nanogram per mL detection of drugs in a complex biological matrix such as human whole blood while maintaining linearity and precision for all compounds across the calibration range.